

16454

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

SCHETTERS Theodorus P.M.  
CARCY Bernard P.D.  
DRAZULINSKI Pascal R.  
GORENFLDT Andre F.

Serial Number: 10/387,573

Group Art Unit: To be assigned

Filed: February 23, 2002

Examiner: To be assigned

For: BABESIA CANIS VACCINE

Corresponding to: EP01200816.5, filed 06 March, 2001

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR 1.97(b)

Assistant Commissioner of Patents  
Washington, D.C. 20231

April 8, 2002

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. These references were cited in the parent case a Search Report for the corresponding European application. Copies of the Search Report and cited references are enclosed.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) completion of the three-month period following filing of the corresponding application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the



lication and that the cited documents be listed on the front page of any patent issuing from this application.

The Patent Office is authorized to charge our Deposit Account No. 02-1334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,

William P Ramey III  
Attorney for Applicants  
Registration No. 44,295

Attorney Docket No. I 2001-004 US

Intervet Inc Patent Department  
Akzo Nobel  
405 State Street  
P.O. Box 318  
Millsboro, DE 19966  
Tel: (302) 933-4034  
Fax: (302) 933-4016

WPE:kmm

RECEIVED

APR 19 2002

TECH CENTER 1600 2900

INFORMATION DISCLOSURE STATEMENT PTO-1-49	Attorney Docket No. I 2001-004 US	Serial No. 10/087,573
	Applicant SCHETTERS et al	
	Filing Date February 28, 2002	Group To be assigned

### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AA	6 045 806	4 4 2000	Schetters			
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						

**RECEIVED**

APR 19 2002

TECH CENTER 1600 2900

### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Translation
AJ	1 050 541 A	11-08-2000	EP	
AK	0 691 131 A	1-10-1996	EP	
AL				
AM				
AN				
AO				
AP				

### OTHER DOCUMENTS

AQ	SCHETTERS T P M ET AL: "Can Babesia infections be used as a Model for Cerebral Malaria?", Parasitology Today, vol. 15, no. 12, December 1999 (1999-12), pages 492-497
AR	CARCY B ET AL: "A 37-kilodalton glycoprotein of Babesia divergens is a major component of a protective fraction containing low-molecular-mass culture-derived exoantigens", Infection and Immunity, American Society for Microbiology, Washington, US, vol. 63, no. 3, March 1995, pages 811-817
AS	GRANDE N ET AL: "Comparison between aserie and seric culture-derived exoantigens of Babesia divergens in their ability to induce immunoprotection in gerbils", Parasitology International, Elsevier Science, Amsterdam, NL, vol. 47, no. 4, December 1998, pages 269-279
AT	CARRET CELINE ET AL: "Characterization and molecular cloning of an adenosine kinase from Babesia canis rossi," European Journal of Biochemistry, vol. 265, no. 3, November 1999, pages 1015-1021
AU	CARRET CELINE ET AL: "Babesia canis canis, Babesia canis vogeli, Babesia canis rossi: Differentiation of the three subspecies by a restriction fragment length polymorphism analysis on amplified small subunit ribosomal RNA genes.", JOURNAL OF EUKARYOTIC MICROBIOLOGY, vol. 46, no. 3, May 1999, pages 298-303
AV	

Examiner

Date Considered